New Fillers Coming Soon!

posted by

Volift and Volbella are two of the latest hyaluronic acid fillers to know about! Both of which are still in clinical trials in the U.S. and not yet FDA-approved, but are currently being used in Europe where they’re showing promising results.

New York facial plastic surgeon Dilip Madnani stated “Volift is supposed to last much longer than the fillers Allergan [the parent company] currently has. It’s a medium consistency, so can be injected more superficially than Voluma, and would be used similar to how Juvederm is currently used. Ideal candidates for Volift are those who have mild to moderate depressions on their face, such as nasolabial folds and marionette lines. The filler is supposed to last up to 15 months.”

Volbella is also gaining anticipation stateside. “Volbella is a thinner consistency and can be used even more superficially than Volift,” says Dr. Madnani. “Ideal candidates will be anyone who has these lines and wants them corrected quickly without much downtime. It is supposed to last up to 12 months.” Dr. Madfes says Volbella best targets fine lines on the skin’s surface, such as “smoker’s lines” on the upper lip.”

We’re hoping to see these new products hit doctors’ offices stateside in late 2016, but at this point, it’s in the hands of the FDA.

April 26, 2016

Hannah Cloe is the brand manager for Med Aesthetics Group. She manages all of Med Aesthetics Group’s digital marketing and branding efforts and has a passion for marketing and the aesthetics industry. Her favorite thing about working at Med Aesthetics Group is getting to collaborate with an amazing team and getting to see our clients’ practices reach their potential. In her free time you can find Hannah reading, writing, and hiking.

Leave a Reply

Your email address will not be published. Required fields are marked *

Book More Patients. Start Today.

Instagram Feed

This error message is only visible to WordPress admins

Error: No connected account.

Please go to the Instagram Feed settings page to connect an account.